{"filing":{"accession_number":"0001437749-26-020501","cik":"0001595248","ticker":"GNPX","company_name":"Genprex, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"gnpx20260611_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926020501/gnpx20260611_8k.htm"},"events":[{"id":10354,"run_id":9081,"accession_number":"0001437749-26-020501","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Genprex received a formal delisting notice from Nasdaq on June 10, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for a compliance period due to a reverse stock split effected on October 21, 2025, and must request a hearing before a Nasdaq Hearings Panel to avoid delisting.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-06-12","submitted_at":null,"items":[{"id":6647,"accession_number":"0001437749-26-020501","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Genprex received a formal delisting notice from Nasdaq on June 10, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for a compliance period due to a reverse stock split effected on October 21, 2025, and faces delisting unless it successfully requests and obtains a hearing before a Nasdaq Hearings Panel. This is a direct and material delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:04:48.310552+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6648,"accession_number":"0001437749-26-020501","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"On June 10, 2026, Genprex received a Nasdaq delisting notice for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period and must request a hearing before a Nasdaq Hearings Panel to avoid delisting. This is a clear and material delisting risk disclosure under Item 8.01, with explicit language that delisting \"could have a material adverse effect on our business\" and would negatively impact stock price, capital access, and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:04:48.310552+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6647,"accession_number":"0001437749-26-020501","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Genprex received a formal delisting notice from Nasdaq on June 10, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for a compliance period due to a reverse stock split effected on October 21, 2025, and faces delisting unless it successfully requests and obtains a hearing before a Nasdaq Hearings Panel. This is a direct and material delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:04:48.310552+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-06-12"},{"id":6648,"accession_number":"0001437749-26-020501","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"On June 10, 2026, Genprex received a Nasdaq delisting notice for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period and must request a hearing before a Nasdaq Hearings Panel to avoid delisting. This is a clear and material delisting risk disclosure under Item 8.01, with explicit language that delisting \"could have a material adverse effect on our business\" and would negatively impact stock price, capital access, and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:04:48.310552+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-06-12"}]}